The United Kingdom and the United States have agreed to a landmark trade agreement that will keep zero levies on British pharmaceutical products entering the American market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has committed to boost expenditure on medicines through the NHS. This commitment secures that tariffs on these crucial products will be held at nothing for a period of 36 months.
This deal is in response to recent statements to dramatically increase duties on patented drug products, with increases discussed up to double the cost.
"This agreement with the Britain strengthens the global environment for innovative medicines and introduces long-overdue equity to U.S.–U.K. drug exports," a release noted.
Trade Significance
Drugs represent one of the UK's largest export categories to the US, which is clearly the primary buyer for major companies like GSK and AstraZeneca.
Statistics reveal that in the 12 months prior to September, the UK shipped medicines worth over eleven billion pounds to the US. This value accounted for nearly one-fifth of total UK exports in that span.
"This agreement protects work, boosts capital expenditure and paves the way for the UK to emerge as a global hub for life sciences," the Business and Trade Secretary stated.
Specific British Pledges
The pact includes several specific changes from the British government:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it considers new medicines to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a target to increase overall NHS spending on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Rebate Cap: The sum drug companies must refund to the NHS to control costs will be restricted at 15%. Previously, refunds exceeded 20%.
Industry Background
This agreement follows a ongoing dispute between the sector and the ministers over spending levels and approval rates.
This friction were intensified by claims that US consumers were paying several times more for the equivalent treatments than patients in the UK and Europe.
Recently, several major pharmaceutical investments in the UK have been halted or cancelled, while major investments have been pledged toward American operations.
A senior figure publicly accepted that the NHS had to spend more on medicines, noting that its expenditure on drugs had declined as a share of its overall budget over the past decade.
